New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:34 EDTBPTHBio-Path resumes Liposomal Grb-2 Phase I trial enrollment
Bio-Path Holdings announced enrollment is now resuming into its Phase I clinical trial evaluating its lead compound, Liposomal Grb-2, in blood cancers. Sufficient drug quantities are now in place to complete Cohort 6 of the trial. To date, Bio-Path has successfully completed five cohorts of the Phase I clinical trial and has treated two patients in the sixth cohort. The trial requires three evaluable patients per cohort. The company intends to evaluate patient results at the end of Cohort 6 to determine if the optimal biological dose has been reached, which would bring a close to the Phase I clinical trial.
News For BPTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 17, 2015
08:36 EDTBPTHBio-Path Holdings reports FY14 EPS (5c), one estimate (4c)
Reports FY14 net loss ($4.5M), primarily due to an increase of approximately $1.1M in general and administrative expense. Reports operating expenses increased by $1.3M to $4.5M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use